{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:25:26Z","timestamp":1794360326780,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.gastro.2016.03.037","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T22:08:10Z","timestamp":1459634890000},"page":"97-109.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Cancer Recurrence Following Immune-Suppressive Therapies in\u00a0Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis"],"prefix":"10.1053","volume":"151","author":[{"given":"Edward","family":"Shelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.03.037_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","volume":"58","author":"Helmick","year":"2008","journal-title":"Part I. Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","article-title":"New IBD genetics: common pathways with other diseases","volume":"60","author":"Lees","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2016.03.037_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2012-201456","article-title":"Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study","volume":"72","author":"Gremese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.gastro.2014.08.003","article-title":"Converging goals of treatment of inflammatory bowel disease from clinical trials and practice","volume":"148","author":"Levesque","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A\u00a0systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.03.037_bib9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200519010-00006","article-title":"TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis","volume":"19","author":"Tobin","year":"2005","journal-title":"BioDrugs"},{"key":"10.1053\/j.gastro.2016.03.037_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2016.03.037_bib12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.03.037_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"10.1053\/j.gastro.2016.03.037_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2016.03.037_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semcancer.2008.10.002","article-title":"Immune escape by Epstein-Barr virus associated malignancies","volume":"18","author":"Munz","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1053\/j.gastro.2016.03.037_bib17","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O'Donovan","year":"2005","journal-title":"Science"},{"key":"10.1053\/j.gastro.2016.03.037_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-0-387-78574-5_11","article-title":"Carcinogenic mechanisms related to immunosuppressive therapy","volume":"146","author":"Perrett","year":"2009","journal-title":"Cancer Treat Res"},{"key":"10.1053\/j.gastro.2016.03.037_bib19","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/ajg.2009.745","article-title":"Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study","volume":"105","author":"Armstrong","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.03.037_bib20","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.03.037_bib21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a Markov model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2011.09.017","article-title":"Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model","volume":"10","author":"Siegel","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/gutjnl-2013-305300","article-title":"The management of immunosuppression in patients with inflammatory bowel disease and cancer","volume":"62","author":"Bernheim","year":"2013","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2016.03.037_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000367861","article-title":"Previous cancer and\/or lymphoma in patients with refractory IBD\u2013pro: anti-TNF or immunosuppressive treatment","volume":"32","author":"Laharie","year":"2014","journal-title":"Dig Dis"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2016.03.037_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000367862","article-title":"Previous cancer and\/or lymphoma in patients with refractory IBD\u2013con: anti-TNF or conventional immunosuppressive treatment","volume":"32","author":"Mantzaris","year":"2014","journal-title":"Dig Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3352","article-title":"Treating rheumatic patients with a malignancy","volume":"13","author":"Elandt","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.gastro.2016.03.037_bib32","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3899\/jrheum.120165","article-title":"Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis\u00a0with traditional and biologic disease-modifying antirheumatic drugs: part II safety","volume":"39","author":"Bombardier","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.gastro.2016.03.037_bib34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib35","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2016.03.037_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.gastro.2016.03.037_bib37","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib38","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.gastro.2016.03.037_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ecco-jcc\/jjv032","article-title":"Incidence, management, and course of cancer in patients with inflammatory bowel disease","volume":"9","author":"Algaba","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2016.03.037_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-TNF\u03b1 therapy","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib41","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1016\/S0016-5085(14)62091-6","article-title":"Thiopurines and anti-TNFs in patients with inflammatory bowel disease and a previous diagnosis of cancer","volume":"146","author":"Onali","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.crohns.2013.12.022","article-title":"Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease","volume":"8","author":"Rajca","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"suppl 1","key":"10.1053\/j.gastro.2016.03.037_bib43","first-page":"i38","article-title":"The influence of anti-TNF or rituximab on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy","volume":"53","author":"Silva-Fernandez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib44","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on pre-existing cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation"},{"key":"10.1053\/j.gastro.2016.03.037_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2016.03.037_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000741","article-title":"Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years","author":"Poullenot","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib47","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S0016-5085(14)60193-1","article-title":"Management and course of inflammatory bowel disease patients with associated cancer","volume":"146","author":"Guerra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib48","doi-asserted-by":"crossref","first-page":"S473","DOI":"10.14309\/00000434-201410002-01665","article-title":"The risk of a second non-melanoma skin cancer with thiopurine and anti-TNF use in inflammatory bowel disease","volume":"109","author":"Scott","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 10","key":"10.1053\/j.gastro.2016.03.037_bib49","first-page":"S808","article-title":"Risk of recurrent non-melanoma skin cancer with methotrexate and anti-TNF use in rheumatoid arthritis","volume":"66","author":"Scott","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/annrheumdis-2014-eular.2568","article-title":"Rates of serious infections and malignancies among rheumatoid arthritis patients receiving either TNF-blocker or rituximab therapy in Finland","volume":"73","author":"Aaltonen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib51","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0016-5085(14)60282-1","article-title":"Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years","volume":"165","author":"Poullenot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib52","first-page":"S342","article-title":"Risk of cancer recurrence or new tumors in RA patients with prior malignancies treated with various biologic agents","volume":"65","author":"Strangfeld","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib53","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.gastro.2016.03.037_bib54","first-page":"4","article-title":"Malignancies in the psoriasis longitudinal assessment and registry (PSOLAR) study: current status of observations","volume":"23","author":"Fiorentino","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib55","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.14309\/00000434-201410002-01633","article-title":"Malignancy outcomes in inflammatory bowel disease patients on immune modulators and anti-tumor necrosis factor therapy","volume":"109","author":"Patel","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.03.037_bib56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jdv.12492","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry","volume":"29","author":"Carretero","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1053\/j.gastro.2016.03.037_bib57","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib58","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/ibd.21487","article-title":"Clinical course of Crohn's disease following treatment of lymphoma","volume":"17","author":"El Mourabet","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2016.03.037_bib59","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of non-melanoma skin cancer in patients with a history of NMSC with the use of immunosuppressant and biologic agents in autoimmune disease","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib61","first-page":"S374","article-title":"Safety of TNF inhibitor therapy in patients who have had a prior malignancy","volume":"66","author":"Bae","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib62","first-page":"S813","article-title":"Risk of cancer in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition","volume":"66","author":"Fagerli","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib63","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2016.03.037_bib64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.gastro.2016.03.037_bib65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.03.037_bib66","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of cancer treatment on inflammatory bowel disease remission and reactivation","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516300506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516300506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T03:10:34Z","timestamp":1600398634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508516300506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0016508516300506"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.03.037","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Recurrence Following Immune-Suppressive Therapies in\u00a0Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}